Arnon P. Kater, MD, PhD, on CLL: Efficacy of Venetoclax in Relapsed or Refractory Disease
EHA25 VirtualArnon P. Kater, MD, PhD, of the University of Amsterdam, Cancer Center Amsterdam, discusses phase IIIb results from the VENICE I trial, which confirmed that venetoclax monotherapy can achieve deep responses and has a tolerable and manageable safety profile in patients with relapsed or refractory chronic lymphocytic leukemia (Abstract S156).
Related Videos
Elias Jabbour, MD, on Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma: Venetoclax and Navitoclax in Relapsed or Refractory Disease
Elias Jabbour, MD, of The University of Texas MD Anderson Cancer Center, discusses study findings that showed venetoclax and navitoclax with chemotherapy is well tolerated, w...
Elizabeth H. Phillips, MD, on DLBCL: Inotuzumab Ozogamicin Plus Chemotherapy in Front-Line Setting
Elizabeth H. Phillips, MD, of the University of Manchester and The Christie Hospital, discusses phase II findings showing inotuzumab ozogamicin plus rituximab, cyclophosphami...
Jorge E. Cortes, MD, on Chronic Phase CML: Comparing Three Starting Doses of Ponatinib
Jorge E. Cortes, MD, of Georgia Cancer Center, discusses interim results from the OPTIC study, which showed a trend toward dose-dependent efficacy and safety, and may provide...
John C. Byrd, MD, on CLL/SLL: Acalabrutinib in Treatment-Naive Patients
John C. Byrd, MD, of The Ohio State University Comprehensive Cancer Center, discusses the mature results of a phase II study showing durable remissions and long-term tolerabi...
Courtney D. DiNardo, MD, on AML: Venetoclax and Azacitidine for Treatment-Naive Patients
Courtney D. DiNardo, MD, of The University of Texas MD Anderson Cancer Center, discusses data from her study of treatment-naive, predominantly older patients with acute myelo...
